Products
Defibrotide was approved in many countries in 2020 as a concentrate for the preparation of an infusion solution (Defitelio).
Structure and properties
Defibrotide is a mixture of single-stranded oligonucleotides derived from porcine intestinal mucosa.
Effects
Defibrotide (ATC B01AX01) has antithrombotic, fibrinolytic, antiadhesive, and anti-inflammatory properties.
Indications
For the treatment of severe hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), in hematopoietic stem cell transplantation (HSCT).
Dosage
According to the SmPC. The drug is administered as an intravenous infusion.
